Related Experiment Videos
Combination antibiotic therapy in the management of intra-abdominal infection
1College of Pharmacy, University of Georgia, Augusta.
Abstract:
Combination antimicrobial regimens consisting of an agent with activity against gram-negative bacilli (an aminoglycoside) plus an agent with anaerobic activity (usually clindamycin or metronidazole) have traditionally been accepted as the standards for the treatment of intra-abdominal infection. Because of the problems of nephrotoxicity and ototoxicity in patients treated with aminoglycosides, clinical trials have been conducted using alternative combination therapy (e.g., aztreonam plus clindamycin) or single beta-lactam antimicrobial agents. Most clinical trials of intra-abdominal infections have been conducted in relatively small patient populations with a variety of low- and high-risk patients. The newer regimens have demonstrated efficacy equivalent to traditional combination therapy in selected patient populations. When selecting an antimicrobial regimen for treatment of intra-abdominal infection, multiple issues should be considered, including demonstrated efficacy in clinical trials, potential for adverse effects, and cost.
Insights
Traditional intra-abdominal infection treatment using aminoglycosides is being challenged. Newer antimicrobial regimens show comparable efficacy with fewer adverse effects, offering safer alternatives for patients.
Area of Science:
- Infectious Diseases
- Pharmacology
- Surgical Infections
Background:
- Intra-abdominal infections (IAIs) traditionally treated with aminoglycosides plus anaerobic agents.
- Aminoglycosides pose risks of nephrotoxicity and ototoxicity.
- Need for alternative antimicrobial strategies in IAI management.
Purpose of the Study:
- Evaluate newer antimicrobial regimens for intra-abdominal infections.
- Compare efficacy and safety of alternative therapies versus traditional regimens.
- Inform antimicrobial selection for IAIs.
Main Methods:
- Review of clinical trials on intra-abdominal infection treatment.
- Analysis of alternative combination therapies (e.g., aztreonam plus clindamycin).
- Inclusion of studies with varied patient populations.
Main Results:
- Newer regimens demonstrated equivalent efficacy to traditional therapy in specific patient groups.
- Alternative therapies may mitigate risks associated with aminoglycosides.
- Efficacy of single beta-lactam agents also explored.
Conclusions:
- Alternative antimicrobial regimens are effective for treating IAIs.
- Selection should consider efficacy, adverse effects (nephrotoxicity, ototoxicity), and cost.
- Evidence supports moving beyond traditional aminoglycoside-based therapy in select cases.